Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, P.R. China.
Int J Mol Med. 2020 Sep;46(3):925-935. doi: 10.3892/ijmm.2020.4662. Epub 2020 Jun 26.
As regards acute myocardial infarction, great success has been achieved in therapies that reduce the effects of myocardial ischemic injury, while few interventions have achieved satisfactory outcomes for myocardial ischemia‑reperfusion (IR) injury. Thus, new research is urgently required to achieve breakthroughs in promising treatments. Neuregulin‑1 (NRG‑1), which is an endothelium‑derived protein and the ligand of ErbB receptors, exerts cardioprotective effects and is rapidly upregulated during IR. NRG‑1/ErbB activates several downstream signaling pathways in response to myocardial IR injury. Previous studies have revealed the protective effects of NRG‑1 during heart failure, and numerous experiments have explored the mechanisms underlying the NRG‑1‑induced cardioprotective effects against myocardial IR injury. In the present review, the progress made in the research of NRG‑1 as a cardioprotective agent during IR and related conditionings is summarized. Furthermore, the potential benefits of NRG‑1 against myocardial IR injury are listed with the prospective use of NRG‑1 in clinical applications.
关于急性心肌梗死，在减轻心肌缺血性损伤的治疗方面已取得巨大成功，而针对心肌缺血再灌注（IR）损伤的干预措施很少能取得满意的效果。因此，迫切需要新的研究来实现有前途的治疗方法的突破。神经调节蛋白 1（NRG-1）是一种内皮衍生蛋白，也是 ErbB 受体的配体，具有心脏保护作用，并在 IR 期间迅速上调。NRG-1/ErbB 在响应心肌 IR 损伤时激活几个下游信号通路。先前的研究揭示了 NRG-1 在心力衰竭期间的保护作用，并且已经进行了大量实验来探讨 NRG-1 诱导的针对心肌 IR 损伤的心脏保护作用的机制。在本综述中，总结了 NRG-1 在 IR 及相关条件下作为心脏保护剂的研究进展。此外，还列出了 NRG-1 对心肌 IR 损伤的潜在益处，并展望了 NRG-1 在临床应用中的应用前景。
